Current Price Action and Market Context
As of 23 Jul 2026, Lupin’s stock closed at ₹2,405.80, down from the previous close of ₹2,514.40. The intraday range saw a high of ₹2,498.90 and a low of ₹2,404.00, indicating some volatility within the session. The stock remains close to its 52-week high of ₹2,530.00, while comfortably above its 52-week low of ₹1,838.65. This price action reflects a consolidation phase after recent gains, with the stock retracing some of its upward momentum.
Technical Trend Shift: From Bullish to Mildly Bullish
The technical trend for Lupin has softened from a clear bullish stance to a mildly bullish one. This subtle shift suggests that while upward momentum remains, it is losing some strength, potentially signalling a period of sideways movement or moderate correction before any further advance.
MACD Analysis
The Moving Average Convergence Divergence (MACD) indicator remains bullish on both weekly and monthly timeframes. This sustained bullishness indicates that the underlying momentum is still positive, with the MACD line above the signal line and histogram bars supporting upward price movement. The MACD’s strength on longer timeframes suggests that the broader trend remains intact despite short-term fluctuations.
RSI Signals
The Relative Strength Index (RSI) presents a mixed scenario. On the weekly chart, the RSI is neutral, offering no clear signal, while on the monthly chart it is bearish. A bearish RSI on the monthly timeframe implies that the stock may be entering an overbought territory or facing weakening momentum, which could lead to a correction or consolidation phase. Investors should monitor RSI levels closely for any move below the 50 mark, which would confirm a loss of bullish momentum.
Bollinger Bands and Moving Averages
Bollinger Bands on both weekly and monthly charts are mildly bullish, indicating that price volatility is contained within an upward trending channel. This suggests that while the stock is not experiencing extreme price swings, it is maintaining a positive trajectory. Daily moving averages reinforce this view, showing a bullish alignment with shorter-term averages positioned above longer-term ones, signalling continued buying interest in the near term.
KST and Dow Theory Perspectives
The Know Sure Thing (KST) indicator is mildly bearish on both weekly and monthly charts, signalling some caution as momentum may be waning. Similarly, Dow Theory readings are mildly bearish on the weekly timeframe but bullish on the monthly, reflecting a divergence between short-term caution and longer-term confidence. This divergence highlights the importance of timeframe in technical analysis and suggests that short-term traders may face choppier conditions compared to long-term investors.
On-Balance Volume (OBV) and Volume Trends
OBV readings are mildly bearish on both weekly and monthly charts, indicating that volume trends are not strongly supporting price advances. This lack of volume confirmation could imply that recent price gains are not backed by robust buying interest, a factor that may limit the sustainability of upward moves.
Comparative Returns and Market Performance
Despite recent technical softness, Lupin’s stock has delivered impressive returns relative to the Sensex. Year-to-date, Lupin has gained 13.91%, while the Sensex has declined by 9.93%. Over the past year, Lupin’s return stands at 26.26%, contrasting with the Sensex’s negative 6.61%. Longer-term performance is even more striking, with Lupin delivering 157.35% over three years and 103.89% over five years, far outpacing the Sensex’s 15.10% and 45.27% respectively. This outperformance underscores Lupin’s resilience and growth potential within the Pharmaceuticals & Biotechnology sector.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Mojo Score Upgrade and Market Capitalisation
Lupin’s Mojo Score has been upgraded to 84.0, reflecting a Strong Buy rating as of 21 Jul 2026, an improvement from its previous Buy grade. This upgrade is indicative of enhanced confidence in the stock’s fundamentals and technical outlook. As a mid-cap company, Lupin occupies a strategic position in the Pharmaceuticals & Biotechnology sector, balancing growth potential with manageable risk.
Technical Summary and Investor Implications
The technical indicators present a nuanced picture. While MACD and moving averages suggest continued bullish momentum, bearish signals from RSI, KST, and OBV caution investors about potential short-term weakness or consolidation. The mildly bullish Bollinger Bands and mixed Dow Theory readings further reinforce this balanced outlook.
For investors, this means that while Lupin remains a fundamentally strong and technically promising stock, caution is warranted in the short term. Monitoring key support levels near ₹2,400 and resistance around the 52-week high of ₹2,530 will be critical. A sustained break above resistance could reignite bullish momentum, whereas a drop below support may signal a deeper correction.
Sector and Peer Context
Within the Pharmaceuticals & Biotechnology sector, Lupin’s technical and fundamental strength stands out. The sector has faced volatility due to regulatory and pricing pressures, but Lupin’s consistent performance and technical resilience position it favourably against peers. Its strong returns relative to the Sensex highlight its ability to navigate sector challenges effectively.
Curious about Lupin Ltd. from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Outlook and Conclusion
Lupin Ltd. is currently navigating a technical transition phase characterised by mixed signals. The stock’s strong long-term momentum, supported by a robust Mojo Score upgrade to Strong Buy, suggests that the underlying fundamentals remain solid. However, short-term technical indicators advise prudence as momentum indicators like RSI and KST show signs of weakening.
Investors with a medium to long-term horizon may view current price levels as an opportunity to accumulate, given Lupin’s impressive relative returns and sector positioning. Conversely, short-term traders should watch for confirmation of trend direction through volume and momentum indicators before committing to fresh positions.
In summary, Lupin’s technical landscape is a blend of cautious optimism and measured risk, reflecting the complexities of the Pharmaceuticals & Biotechnology sector in the current market environment.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
